Calypte und die Zeit nach AIDS2004 in Bangkok
Seite 165 von 203 Neuester Beitrag: 19.01.06 14:27 | ||||
| Eröffnet am: | 05.07.04 15:03 | von: Kade_I | Anzahl Beiträge: | 6.056 |
| Neuester Beitrag: | 19.01.06 14:27 | von: Der_wahre_. | Leser gesamt: | 180.350 |
| Forum: | Hot-Stocks | Leser heute: | 196 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 163 | 164 | | 166 | 167 | ... 203 > | ||||
wenn du noch nicht einmal weißt das die ID "schewardnadse" nicht zu mir gehört solltest du mal mit dem denken anfangen.
und zu leobmw stehe ich, jedoch über einige postings könnte man reden.
Ich möchte mal die ID sehen mit der Anzahl an Posting die nicht mal über die Strenge geschlagen hat - jedoch geht es bei mir eher darum das ich nicht zu Kreuze krieche wie das manche wollen, was ich jedoch niemals tun werde.
Und du musst in Zukunft mal besser Recherchieren bevor du Wertungen abgibst.
Gruß
leo
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Er ist der Meinung, dass wenn er geschmeidige Wörter benutzt so einiges besser und getarnt klingen lässt und er dabei nicht erwischt wird..
Meist ist es auch leider so, das viele reinfallen und die Aggression nicht beherrschen können.
Leider geht es dem lieben ARIVA TEAM genauso nach meiner Meinung........
Gruß
C.O
zu dir, mein ganz spezieller kade: wie ich geschleimt habe, kannst du anhand meines öffentlichen postings als joelu_nachfolger lesen, gelle?
hauptsache, ihr versucht mir für euer fehlverhalten die schuld in die schuhe zu schieben!
schonmal aufgefallen, dass einige meiner schwarzen sterne sogar in grüne umgewandelt wurden? das kommt nicht einfach so aus nächstenliebe der mods.
02/15/05 15:31:39 0.37 0.36 0.38 -378800 §
02/15/05 15:31:44 0.37 0.36 0.38 500 §
02/15/05 15:33:39 0.37 0.37 0.39 0 §
02/15/05 15:34:16 0.38 0.38 0.39 62100 §
02/15/05 15:37:26 0.38 0.38 0.39 0 §
02/15/05 15:38:03 0.39 0.38 0.39 65300 §
02/15/05 15:38:10 0.39 0.38 0.39 0 §
02/15/05 15:40:13 0.39 0.39 0.40 0 §
02/15/05 15:41:06 0.40 0.39 0.40 120700 §
02/15/05 15:41:30 0.40 0.39 0.40 0 §
02/15/05 15:41:31 0.40 0.39 0.41 0 §
02/15/05 15:43:11 0.39 0.39 0.40 28000 §
02/15/05 15:43:16 0.39 0.38 0.41 0 §
02/15/05 15:45:10 0.39 0.38 0.39 0 §
02/15/05 15:46:10 0.39 0.38 0.39 0 §
02/15/05 15:49:13 0.39 0.38 0.39 25000§
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
euer ausstiegszeitpunkt dürft bald gekommen sein:
Time & Sales most recent next page
Rec. Time Action Price Volume
9:57:28 AM Ask 0.42 103100
9:57:28 AM Ask 0.42 119100
9:57:28 AM Trade 0.42 1000
9:57:28 AM Trade 0.42 1000
9:57:26 AM Trade 0.42 17800
9:57:22 AM Trade 0.42 2000
9:57:22 AM Trade 0.42 8000
9:57:22 AM Ask 0.42 135600
9:57:18 AM Bid 0.41 41500
9:57:16 AM Trade 0.41 8500
9:57:04 AM Trade 0.42 1000
9:57:04 AM Trade 0.42 9600
9:57:02 AM Trade 0.42 9100
9:57:02 AM Trade 0.38 7000
First Trial Begins in Uganda
PLEASANTON, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has initiated a clinical trial program of its Aware(TM) rapid HIV-1/2 test platform in Africa. The first trials are being conducted in the Republic of Uganda HIV/AIDS Reference and Quality Assurance Laboratory (HRL), Uganda Virus Research Institute, in Entebbe. The trial will evaluate the sensitivity and specificity of the Company's rapid HIV 1/2 Antibody Tests using; Blood, Oral Fluid and Urine as a specimen.
The trials will evaluate approximately 350 subjects and are being performed under the direction of Dr. Benon Biryahwaho, Laboratory Coordinator at the Uganda Virus Research Institute. This study represents the first regulatory trials to be performed on Aware(TM) tests in sub-Saharan Africa. The Company expects data collection to be completed in the second quarter of this year. Contingent upon positive results from the trial, the Company expects to file for regulatory approval in Uganda by mid-2005.
"Getting these trials underway is an important milestone for Calypte," stated Dr. J. Richard George, President and CEO of Calypte. "We have made great efforts to adhere to our timelines to bring these tests to market, and we are pleased to kick off the African regulatory effort with Dr. Biryahwaho, who has long been a central figure in the Ugandan HIV control effort."
Dr. Benon Biryahwaho commented, "We have continued to assess new technologies for the detection of HIV/AIDS in order that the Ugandan Public should benefit from the most advanced scientific developments in the delivery of AIDS services and care. HIV/AIDS testing empowers people to be informed and hence make appropriate choices. In Uganda, the problem is access and equity. Calypte has made it easier by formulating simple rapid technologies."
The Company intends to initiate additional regulatory trials in key African and Far East markets over the course of 2005. Additionally, the Company expects to begin clinical trials in the coming months utilizing its first commercial application of the technology acquired from Ani Biotech in October 2004. These additional studies using the Ani platform will be initially conducted by Dr. Biryahwaho in the coming months and will continue in other key markets throughout 2005.
Dr. George added, "We believe the Ani format will provide additional options to the African market. The technology transfer for the rapid HIV-1/2 tests using the Ani platform has occurred much quicker than initially expected. We have been able to successfully transfer the technology to our Rockville manufacturing facility, allowing us to qualify both platforms and initiate the Ani trials in Uganda in the coming months. The Ani platform is well suited for both the professional markets as well as over-the-counter applications and represents the future platform for all of the Calypte's diagnostic endeavors."
"We have been gratified by the progress that has been made and the cooperation that we have received from various regulatory agencies in our most important target countries in the region, and will issue further updates as these efforts continue," concluded Dr. George.
About Uganda:
Uganda, located in sub-Saharan Africa has a population of over 26 million according to the U.S. Central Intelligence Agency Fact book. According to the UNAIDS 2004 report on the global AIDS epidemic, as of the end of 2003, approximately 530,000 adults and children living with HIV/AIDS, down from an estimated 620,000 two years prior. The Company estimates that foreign and donor agency sources including USAID, the Global Fund and the World Bank, funded over $100 million in 2004 for AIDS testing and treatment in Uganda. It is estimated that over 1 millions HIV diagnostic tests were conducted in Uganda in 2004, most of these rapid tests.
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 Incidence EIA as well as tests that can determine HIV antibody status without the need for blood. Calypte is engaged in developing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.
Company Contact: Investor Relations Contact:
Richard George, CEO Tim Clemensen,
(925) 730-7200 Rubenstein Investor Relations
email: rgeorge@calypte.com Phone: (212) 843-9337
email: tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
-0- 02/15/2005
/CONTACT: Richard George, CEO of Calypte Biomedical Corporation,
+1-925-730-7200, rgeorge@calypte.com; Tim Clemensen of Rubenstein Investor
Relations, +1-212-843-9337, tclemensen@rubensteinir.com, for Calypte
Biomedical Corporation/
/Web site: http://www.calypte.com /
(HIV)
CO: Calypte Biomedical Corporation
ST: California
IN: MTC HEA
SU: PDT
NM
-- NYTU143 --
4327 02/15/200509:56 ESThttp://www.prnewswire
02/15/05 15:56:59 0.41 0.41 0.41 197200 §
02/15/05 15:57:16 0.41 0.41 0.41 35200 §
02/15/05 15:57:19 0.41 0.41 0.42 0 §
02/15/05 15:57:21 0.42 0.41 0.42 8000 §
02/15/05 15:57:25 0.42 0.41 0.42 19800 §
02/15/05 15:58:35 0.42 0.41 0.42 177700 §
02/15/05 15:58:44 0.42 0.42 0.43 0§
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Laut Deinen Aussagen hätten bei Calypte doch Ende 2004 schon die Lichter ausgehen sollen ! Und schon wiedermal falsch gelegen ...
;-)
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
und an die vermutung, dass die testergebnisse in china nicht befriedigend waren, ist völlig aus der luft gegriffen?
kade, die lichter wären auch ausgegangen, wenn marr nicht nochmal kurz für weitere 3 monate geld in den laden gepumpt hätte. wie lange sie das wohl noch machen werden?
fragen über fragen...
ts ts...testen kostet auch...
"…Looking at the African strategy. What is our timelines? Again, we’re going to tell you exactly what our timelines are, and we want you, as you have in the past, to hold us accountable to those timelines. We’re going to hit every one of them. For the African strategy we are identifying the regulatory requirements in those countries. We are knocking them off as we can begin that process. The process has already begun. The product for the African launch is going to be made in Thailand. As we have announced before, we have a strategic alliance, a contract with a company in Petcha Boon Thailand. That company is Pacific Biotech. We have people right now in Petcha Boon transferring the technology to Pacific Biotech to get started making tests for the African launch. That process is probably two thirds of the way completed. We have another group of people who will be leaving the day after Thanksgiving to go there to complete the process. The 1st lots of tests have been made already in Petcha Boon and they did meet our specifications. So, we feel like this project is going extremely well. That process will be completed by the end of 2004 and we do plan to launch into Africa the very first part of 2005.
Looking at the African opportunity; the purpose of this slide is simply to illustrate the point that, even with a very low penetration rate, we can have significant sales in Africa, and we believe that we have a product that is going to be very acceptable in this market and we feel like it will be no problem at all to achieve the penetration rates that are necessary to lead us to profitability."
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Time & Sales most recent next page
Rec. Time Action Price Volume
11:33:56 AM Trade 0.39 3000
11:20:26 AM Bid 0.38 17100
11:16:56 AM Trade 0.38 3000
11:16:56 AM Trade 0.38 2000
11:16:56 AM Bid 0.38 11100
11:15:42 AM Trade 0.39 1000
11:15:42 AM Ask 0.39 21300
11:13:30 AM Bid 0.38 13100
11:13:22 AM Bid 0.38 16100
11:11:54 AM Bid 0.38 16900
11:11:22 AM Bid 0.38 16100
11:10:44 AM Trade 0.39 600
11:09:24 AM Bid 0.38 16900
11:09:24 AM Bid 0.38 17400
11:09:20 AM Trade 0.38 6800
11:09:20 AM Bid 0.38 18200